Pharmaceuticals Analysts, along with Intercept Pharmaceuticals, discuss the study of Obeticholic Acid (OCA) on an Analyst/Industry conference call to be held on April 18.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on ICPT:
- Intercept to Announce First Quarter 2023 Financial Results and Provide Update on Commercial Launch Strategy for NASH on April 27, 2023
- Piper Sandler pharmaceuticals analysts to hold analyst/industry conference call
- Piper ups Intercept target, sees ‘significant share gains’
- Intercept management to meet with Piper Sandler
- Intercept Announces FDA Advisory Committee Meeting Date for Obeticholic Acid as a Treatment for Pre-Cirrhotic Liver Fibrosis due to NASH